MA49693A - Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue - Google Patents

Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue

Info

Publication number
MA49693A
MA49693A MA049693A MA49693A MA49693A MA 49693 A MA49693 A MA 49693A MA 049693 A MA049693 A MA 049693A MA 49693 A MA49693 A MA 49693A MA 49693 A MA49693 A MA 49693A
Authority
MA
Morocco
Prior art keywords
arnrep
heterological
compositions
ensure
methods
Prior art date
Application number
MA049693A
Other languages
English (en)
Inventor
Darrell J Irvine
Tasuku Kitada
Mariane Bandeira Melo
Ely Blanton Porter
Der Neut Kolfschoten Marijn Van
Ronald Vogels
Ron Weiss
Original Assignee
Janssen Vaccines & Prevention Bv
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv, Massachusetts Inst Technology filed Critical Janssen Vaccines & Prevention Bv
Publication of MA49693A publication Critical patent/MA49693A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA049693A 2017-07-28 2018-07-27 Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue MA49693A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538070P 2017-07-28 2017-07-28
US201762546259P 2017-08-16 2017-08-16

Publications (1)

Publication Number Publication Date
MA49693A true MA49693A (fr) 2020-06-03

Family

ID=63407511

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049693A MA49693A (fr) 2017-07-28 2018-07-27 Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue

Country Status (12)

Country Link
US (2) US11235051B2 (fr)
EP (1) EP3658179B1 (fr)
JP (1) JP7311489B2 (fr)
KR (1) KR102806640B1 (fr)
CN (1) CN111163799A (fr)
AU (1) AU2018306614B2 (fr)
BR (1) BR112020001052A2 (fr)
CA (1) CA3071011A1 (fr)
IL (1) IL272281B2 (fr)
MA (1) MA49693A (fr)
SG (1) SG11202000019RA (fr)
WO (1) WO2019023566A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021010611A2 (pt) * 2018-12-14 2021-08-24 Glaxosmithkline Biologicals S.A. Composições e métodos de vacina de reforço (prime boost) heterólogo
US11026894B2 (en) 2019-01-10 2021-06-08 Massachusetts Institute Of Technology Lipid nanoparticles and use thereof to deliver RNA polynucleotides
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN114980920A (zh) 2019-11-18 2022-08-30 詹森生物科技公司 基于突变体calr和jak2的疫苗及其用途
CA3171231A1 (fr) * 2020-03-09 2021-09-16 Sean Michael Sullivan Compositions et methodes pour l'induction de reponses immunitaires
WO2022009052A2 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
CN116171150A (zh) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 冻干脂质纳米颗粒的方法
CA3211197A1 (fr) 2021-02-23 2022-09-01 Janssen Vaccines & Prevention B.V. Mutation de proteine d'enveloppe du vih stabilisant un trimere
CN117295817A (zh) 2021-03-22 2023-12-26 生命编辑制药股份有限公司 Dna修饰酶及其活性片段和变体以及使用方法
CN115232824B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
WO2023034927A1 (fr) * 2021-09-02 2023-03-09 Replicate Bioscience, Inc. Alphavirus modifiés à protéines non structurales hétérologues
WO2023156505A1 (fr) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimère stabilisant les mutations de protéines d'enveloppe du vih r304v, n302m et t320l
IL316186A (en) * 2022-04-26 2024-12-01 Strand Therapeutics Inc Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof
CN116064597B (zh) * 2023-01-17 2024-04-26 北京大学 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
JP4495588B2 (ja) 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 安定なアデノウイルスベクターおよびその増殖方法
PL215165B1 (pl) 2002-04-25 2013-10-31 Crucell Holland Bv Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego
US20050208020A1 (en) * 2003-11-12 2005-09-22 Doolan Denise L Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
SI2163260T1 (sl) 2004-01-23 2017-07-31 Msd Italia S.R.L. Nosilci šimpanzjih adenovirusnih cepiv
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
EP2146760B1 (fr) 2007-04-30 2018-10-10 Medtronic MiniMed, Inc. Remplissage de réservoir, gestion des bulles d'air, et systèmes et procédés d'administration de milieu de perfusion associés
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
CA2749325C (fr) 2009-02-02 2021-03-30 Okairos Ag Sequences d'acide amine et d'acide nucleique d'adenovirus simien, vecteurs les contenant, et utilisations afferentes
EP2451475A2 (fr) 2009-07-06 2012-05-16 Novartis AG Molécules d'arn autorépliquantes et leurs utilisations
TW201116294A (en) * 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
US11291635B2 (en) * 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
PL2655604T3 (pl) * 2010-12-14 2019-02-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom
AU2012243039B2 (en) * 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CA2841047A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Compositions immunogenes et leurs utilisations
JP2015522581A (ja) * 2012-07-06 2015-08-06 ノバルティス アーゲー サイトメガロウイルスタンパク質の複合体
US20140271714A1 (en) * 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
JP2017527564A (ja) 2014-09-03 2017-09-21 バヴァリアン ノルディック エー／エス 免疫応答の増進を目的とする方法及び組成物
WO2016187613A1 (fr) * 2015-05-21 2016-11-24 Janssen Vaccines & Prevention B.V Procédés et compositions pour induire une immunité protectrice contre l'infection par un filovirus et/ou contre la maladie

Also Published As

Publication number Publication date
CN111163799A (zh) 2020-05-15
US11964007B2 (en) 2024-04-23
EP3658179A1 (fr) 2020-06-03
IL272281B (en) 2022-12-01
JP7311489B2 (ja) 2023-07-19
IL272281B2 (en) 2023-04-01
BR112020001052A2 (pt) 2020-09-08
SG11202000019RA (en) 2020-02-27
US20220111033A1 (en) 2022-04-14
EP3658179B1 (fr) 2025-09-17
AU2018306614B2 (en) 2024-08-29
WO2019023566A1 (fr) 2019-01-31
CA3071011A1 (fr) 2019-01-31
KR102806640B1 (ko) 2025-05-12
JP2020528911A (ja) 2020-10-01
AU2018306614A1 (en) 2020-01-30
IL272281A (en) 2020-03-31
US20200230225A1 (en) 2020-07-23
US11235051B2 (en) 2022-02-01
KR20200037818A (ko) 2020-04-09
EP3658179C0 (fr) 2025-09-17

Similar Documents

Publication Publication Date Title
IL289046A (en) Preparations and methods for inhibiting antigens of a certain lineage
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
EP3355954A4 (fr) Méthodes et compositions d'administration
EP3271482A4 (fr) Compositions et méthodes pour inhiber l'expression génique du facteur xii
IL266398A (en) Liver organoid preparations, methods for their production and their uses
EP3328363A4 (fr) Compositions et méthodes d'immunomodulation
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
IL251823A0 (en) Dedicated elongated recombinant polypeptide conjugate preparations and methods for their preparation
EP3445407A4 (fr) Compositions et méthodes d'immunothérapie cellulaire
EP3510152A4 (fr) Méthodes et compositions pour moduler l'expression génique
EP3802553A4 (fr) Compositions contenant du silicium et procédés d'utilisation associés
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
DK3157959T3 (da) Monoklonale antistoffer mod her2-epitop og fremgangsmåder til anvendelse deraf
SI3356408T1 (sl) Humanizirana protitelesa proti človeškemu CD19 in postopki uporabe
MA43378A (fr) Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
IL271144A (en) Methods and compositions for reducing the immunogenicity of chimeric notch receptors
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
MA71468A (fr) Compositions et méthodes pour diminuer l'expression de tau
EP3258925A4 (fr) Méthodes et compositions pour réduire la vidange gastrique
EP3436031A4 (fr) Nouvelle construction d'arn et méthodes d'utilisation de cette dernière pour améliorer les effets thérapeutiques de cellules cytotoxiques et de cellules souches
PT3310812T (pt) Anticorpos anti-her2 e métodos de utilização
EP3291794A4 (fr) Méthodes et compositions pour favoriser la pousse des cheveux
EP3302588A4 (fr) Compositions et méthodes pour l'adhérence à des surfaces
EP3352800A4 (fr) Méthodes et compositions pour réduire les métastases
EP3436467A4 (fr) Nouvelles compositions et méthodes thérapeutiques